Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions. Mussini C, et al. Among authors: sighinolfi l. AIDS. 2005 Feb 18;19(3):287-94. AIDS. 2005. PMID: 15718839
Treatment-related factors and highly active antiretroviral therapy adherence.
Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, Mura MS, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Trotta MP, et al. Among authors: sighinolfi l. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S128-31. doi: 10.1097/00126334-200212153-00008. J Acquir Immune Defic Syndr. 2002. PMID: 12562035 Review.
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G. Saracino A, et al. Among authors: sighinolfi l. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98. doi: 10.1097/00126334-200412150-00011. J Acquir Immune Defic Syndr. 2004. PMID: 15577415 Clinical Trial.
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
Cozzi-Lepri A, De Luca A, Phillips AN, Bongiovanni M, Di Giambenedetto S, Mena M, Moioli MC, Arlotti M, Sighinolfi L, Narciso P, Lichtner M, Cauda R, Monforte Ad; ICoNA Study Group; UCSC-Roma HIV Cohort Study Group; IMIT Study Group. Cozzi-Lepri A, et al. Among authors: sighinolfi l. J Infect Dis. 2006 Jul 1;194(1):20-8. doi: 10.1086/504265. Epub 2006 May 16. J Infect Dis. 2006. PMID: 16741878 Free article.
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort. Torti C, et al. Among authors: sighinolfi l. J Antimicrob Chemother. 2007 Jun;59(6):1141-7. doi: 10.1093/jac/dkm100. Epub 2007 Apr 13. J Antimicrob Chemother. 2007. PMID: 17434879
Predictors of AIDS-defining events among advanced naïve patients after HAART.
Torti C, Lapadula G, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Pietro MD, Migliorino G, Quiros-Roldan E, Ladisa N, Sighinolfi L, Gatti F, Carosi G; Italian MASTER Cohort. Torti C, et al. Among authors: sighinolfi l. HIV Clin Trials. 2007 May-Jun;8(3):112-20. doi: 10.1310/hct0803-112. HIV Clin Trials. 2007. PMID: 17621458
204 results